Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
To Evaluate the Safety and Efficacy of Microwave Ablation for the Treatment of Malignant
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for this study:
- Unsuitable for surgical resection but local ablation is indicated, however, the distance between tumour and vessels is smaller than 1 cm.
- Have at least one, but less than or equal to 3 tumors.
- Each tumor must be ≤ 5 cm in diameter.
- Child-Pugh class A-B.
- Eastern Cooperative Oncology Group (ECOG) score of 0-1.
- American Society of Anaesthesiologists (ASA) score ≤ 3.
- Adequate bone marrow and liver function (1). Platelet count ≥ 100 K/Μl(2). Total bilirubin ≦ 2 mg/dL(3). alanine transaminase (ALT) and aspartate transaminase (AST) < 5 x upper limit of normal (4). prothrombin time (PT)- international normalized ratio (INR) ≦ 2.0.
- The disease status is not suitable to receive transarterial chemoembolization or other standard treatment.
- Prior Informed Consent Form.
- Life expectancy of at least 3 months.
Exclusion Criteria:
Patients presenting with any of the following will not be enrolled into this study:
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception.
- Received treatment with an investigational agent/ procedure within 30 days prior to microwave ablation.
- Patients who cannot tolerate radiofrequency ablation (RFA) procedure.
- Known history of human immunodeficiency virus (HIV) infection.
- Concurrent extrahepatic cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Microwave ablation (MWA)
|
Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor evaluation
Time Frame: 1 month after treatment
|
Tumor response will be evaluated by abdominal computed tomography (CT) or magnetic resonance imaging (MRI).
|
1 month after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eastern Cooperative Oncology Group (ECOG) evaluation
Time Frame: up to two years
|
Complete an Eastern Cooperative Oncology Group (ECOG) evaluation
|
up to two years
|
|
Clinical laboratory assessment
Time Frame: up to two years
|
Collect blood sample for hematology evaluation
|
up to two years
|
|
Conduct computed tomography (CT) or magnetic resonance imaging (MRI) scans for tumour response evaluation
Time Frame: up to two years
|
Subjects will still be followed-up in the event of disease progression in order to document local recurrence.
|
up to two years
|
|
Review concomitant medications
Time Frame: up to two years
|
Use of medications will be reviewed and recorded
|
up to two years
|
|
Assess for presence of adverse events
Time Frame: up to two years
|
An adverse event assessment will be performed
|
up to two years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 201603095DIPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.